Important Safety Information
IMPORTANT SAFETY INFORMATION/WHAT IS PADCEV®?
IMPORTANT SAFETY INFORMATION/
WHAT IS PADCEV®?
What is the most important information I should know about PADCEV?
PADCEV may cause serious side effects, including:
Skin reactions. Skin reactions including severe skin reactions have happened in people treated with PADCEV and may be more common when PADCEV is given with pembrolizumab. In some cases, these severe skin reactions have caused death. Most severe skin reactions occurred during the first cycle of treatment but may happen later. Your healthcare provider will monitor you, may stop your treatment with PADCEV completely or for a period of time (temporarily), may change your dose, and may prescribe medicines if you get skin reactions. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction:
• Target lesions (skin reactions that look like rings)
• Rash or itching that continues to get worse
• Blistering or peeling of the skin
• Painful sores or ulcers in mouth or nose, throat, or genital area
• Fever or flu-like symptoms
• Swollen lymph nodes
See “What are the possible side effects of PADCEV?” for more information about side effects.
Before receiving PADCEV, tell your healthcare provider about all of your medical conditions, including if you:
• Are currently experiencing numbness or tingling in your hands or feet.
• Have a history of high blood sugar or diabetes.
• Have liver problems.
• Are pregnant or plan to become pregnant. PADCEV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with PADCEV.
• Are breastfeeding or plan to breastfeed. It is not known if PADCEV passes into your breast milk. Do not breastfeed during treatment and for 3 weeks after the last dose of PADCEV.
Females who are able to become pregnant:
• Your healthcare provider should do a pregnancy test before you start treatment with PADCEV.
• You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of PADCEV.
Males with a female sexual partner who is able to become pregnant:
• If your female partner is pregnant, PADCEV can harm the unborn baby.
• You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of PADCEV.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking PADCEV with certain other medicines may cause side effects.
What are the possible side effects of PADCEV?
PADCEV may cause serious side effects, including:
Skin Reactions. See “What is the most important information I should know about PADCEV?”
High blood sugar (hyperglycemia). An increase in blood sugar is common during treatment with PADCEV. Severe high blood sugar, a serious condition called diabetic ketoacidosis (DKA), and death have happened in people with and without diabetes treated with PADCEV. Tell your healthcare provider right away if you have any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.
Lung problems. PADCEV may cause severe or life-threatening inflammation of the lungs that can lead to death. These severe problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.
Nerve problems. Nerve problems, called peripheral neuropathy, are common during treatment with PADCEV and can sometimes be severe. Nerve problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet or muscle weakness.
Eye problems. Certain eye problems are common during treatment with PADCEV. Tell your healthcare provider right away if you have dry eyes, increased tearing, blurred vision, or any vision changes. You may use artificial tear substitutes to help prevent or treat dry eyes.
Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation). If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, blister, peeling skin or discomfort at the infusion site.
Your healthcare provider may decrease your dose of PADCEV, or temporarily or completely stop your treatment with PADCEV if you have severe side effects.
If your healthcare provider prescribes PADCEV in combination with pembrolizumab for you, also read the Medication Guide that comes with pembrolizumab for important information about pembrolizumab.
The most common side effects of PADCEV when used in combination with pembrolizumab include:
• Changes in liver function and kidney function tests
• Rash. See “What is the most important information I should know about PADCEV?”
• Increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”
• Numbness or tingling in your hands or feet. See “Nerve problems”
• Increased lipase (a test done to check your pancreas)
• Decreased white blood cell, red blood cell, and platelet counts
• Tiredness
• Decreased sodium, phosphate, and protein (albumin) in the blood
• Itching
• Diarrhea
• Hair loss
• Decreased weight
• Decreased appetite
• Increased uric acid in the blood
• Increased or decreased potassium
• Dry eye. See “Eye problems”
• Nausea
• Constipation
• Change in sense of taste
• Urinary tract infection
The most common side effects of PADCEV when used alone include:
• Increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”
• Changes in liver and kidney function tests
• Decreased white blood cell, red blood cell, and platelet counts
• Rash. See “What is the most important information I should know about PADCEV?”
• Tiredness
• Numbness or tingling in your hands or feet. See “Nerve problems”
• Decreased protein (albumin), sodium, and phosphate in the blood
• Hair loss
• Decreased appetite
• Diarrhea
• Nausea
• Itching
• Increased uric acid in the blood
• Dry eye. See “Eye problems”
• Change in sense of taste
• Constipation
• Increased lipase (a blood test done to check your pancreas)
• Decreased weight
• Stomach (abdominal) pain
• Dry skin
PADCEV may cause fertility problems in females and males, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.
These are not all the possible side effects of PADCEV.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
WHAT IS PADCEV®?
PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery.
• PADCEV may be used with pembrolizumab (also known as Keytruda®), or
• PADCEV may be used alone if you:
–have received an immunotherapy medicine and chemotherapy that contains platinum, or
–are not able to receive a chemotherapy that contains the medicine cisplatin and you have received 1 or more prior therapy.
It is not known if PADCEV is safe and effective in children.
Please see full Prescribing Information/Patient Information for more information, including risk of Serious Side Effects.
You are leaving PADCEV.com
By clicking “go to link” below, you are leaving an Astellas Pharma US, Inc. and Seagen Inc. website. Astellas Pharma US, Inc. and Seagen Inc. are not responsible for the information or services on any third-party sites.
This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Astellas Pharma US, Inc. and/or Seagen Inc. of the site, its contents, or the owner of the site. Please review the privacy policy and terms of use of the site to understand how your information will be processed.
Thank you for visiting our site.
Cancel
WHAT IS PADCEV®
(enfortumab vedotin-ejfv)?
PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery.
• PADCEV may be used with pembrolizumab (also known as Keytruda®), or
• PADCEV may be used alone if you:
- have received an immunotherapy medicine and chemotherapy that contains platinum, or
- are not able to receive a chemotherapy that contains the medicine cisplatin and you have received 1 or more prior therapy.
It is not known if PADCEV is safe and effective in children.
The product information provided on this website is intended for residents of the United States.
ATTENTION: PLEASE READ THESE TERMS OF USE CAREFULLY BEFORE USING THIS WEB SITE. BY USING THIS WEB SITE, INCLUDING ANY SERVICES PROVIDED ON OR THROUGH THIS WEB SITE, YOU INDICATE THAT YOU ACCEPT THESE TERMS. IF YOU DO NOT ACCEPT THESE TERMS, DO NOT USE THIS SITE.
Astellas Pharma US, Inc. (Astellas) and Seagen Inc. (Seagen) may at any time revise this Terms of Use statement by updating this posting, so you should periodically examine the current Terms of Use to which you are bound. Certain provisions of these Terms of Use may be superseded by expressly designated legal notices or terms located on particular pages at this Site.
GENERAL INFORMATION. This site contains information about an Astellas and Seagen product that may be of interest to Astellas and Seagen customers, shareholders and employees, as well as to members of the health care community and the general public. Please feel free to browse this web site. Your access and use of the information herein are subject to the following terms and conditions, and all applicable laws. By accessing and browsing this web site, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Astellas or Seagen.
PRIVACY. Policies concerning the use of your personal information are set forth in the Astellas Privacy Policy and Seagen Privacy Policy, respectively, and are incorporated by reference herein. By using this Site or the services provided by or through this Site (services), you agree to waive and release Astellas and Seagen from any claim or liability in connection with the collection, use, or disclosure of information consistent with Astellas and/or Seagen privacy policies.
SITE CONTENT. All material on the Site including, but not limited to, text, images, graphics, documents, audio or video (collectively, the Site Content) are protected under applicable copyright laws. You may copy, download or print Site Content for your personal, non-commercial purposes only but no modification or further reproduction of content is permitted. The Site Content may not otherwise be copied, downloaded, reproduced, deleted, modified, republished, retransmitted, displayed, or used to create derivative works without the express written permission of Astellas and Seagen.
Trademarks, service marks, trade dress, logos, designs, and slogans appearing on this site are owned by Astellas and/or Seagen, their Affiliate companies, their licensors or their partners and may not be used for advertising or publicity purposes, or to indicate any affiliation with or endorsement by Astellas or Seagen, except with the express written permission of Astellas and Seagen.
Nothing contained in this website should be construed as granting a license to, or right in, any trademarks, patents, or copyrights of Astellas or Seagen or any other party.
You are solely responsible for all the content including, but not limited to text, photographs, caricatures, illustrations, designs, icons, articles, audio clips, and video clips (collectively, User Content) that you post, e-mail, or otherwise transmit via this Site. Astellas and Seagen do not guarantee the accuracy, integrity, or quality of User Content. With the exception of information covered by Astellas’ or Seagen’s privacy policies, any User Content you send to Astellas or Seagen shall be deemed to be non-confidential and Astellas and Seagen shall have no obligation of any kind with respect to such information and shall be free to reproduce, use, disclose, and distribute the information to others without limitation. Astellas and Seagen shall be free to use any ideas, concepts, know-how or techniques contained in such information for any purpose whatsoever including but not limited to developing, manufacturing and marketing products incorporating such information.
The content or material Astellas and Seagen provide through the Site is provided for informational purposes only and should not be construed as medical, legal, financial, investment, or other professional advice or opinion. Astellas and Seagen do not offer personalized medical advice or patient-specific treatment advice. Only your doctor or other health care professional can determine if a product described in this web site is appropriate for you. Use of this Site is not a substitute for a call or visit to, or consultation with, your physician or healthcare professional. You should not rely on the Site or any other service offered by or through this Site for medical diagnosis or treatment. YOU SHOULD NEVER DISREGARD OR DELAY SEEKING MEDICAL ADVICE BECAUSE OF SOMETHING THAT YOU HAVE SEEN ON THIS SITE. PLEASE CONSULT WITH YOUR DOCTOR, OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL, BEFORE USING ANY PRODUCT DISCUSSED ON THIS SITE.
OBLIGATIONS OF SITE VISITORS OR USERS. You agree not to do any of the following while visiting or using the Site or any services provided by or through this Site: Impersonate or misrepresent your affiliation with any person or entity; except as expressly permitted by the rules of this Site, post or transmit any unsolicited advertising, promotional materials, (junk mail), (spam), (chain letters), or any other form of solicitation on the Site or through the Services; post or transmit any information or material that is defamatory, offensive, indecent, obscene, or unlawful; post or transmit any information or software which contains a virus, trojan horse, worm or other harmful components; violate any applicable law or regulation, including without limitation any local, state, provincial, national or international law, any export control laws, or any regulations promulgated by any state or federal authority; access or use password protected, secure or non-public areas of the Site without authorization; or frame, repackage, or otherwise re-distribute any portion of the Site.
Astellas or Seagen may, at their discretion, take any action they deem necessary, including, but not limited to, termination of access to the Site, if Astellas or Seagen believe a user's conduct or content fails to conform to these terms and conditions or may create liability for Astellas or Seagen, their partners, their suppliers or other users. Astellas or Seagen will not be liable to you or any third party as a result of such termination and modification. The terms and conditions provided in the Terms of Use will survive any such termination and modification.
LINKS TO OTHER WEB SITES. Astellas and Seagen provide links on this Site to other Web sites that are not maintained by or under the control of Astellas or Seagen solely as a convenience to you. If you use these links, you will leave this Site. Please remember that linked sites are not necessarily Astellas or Seagen sites and the information could change without Astellas’ or Seagen’s knowledge. Third party linked sites and their contents should not be attributed to Astellas or Seagen (or any of their affiliated companies) in any manner. Astellas and Seagen have not attempted to verify the truth or accuracy of any third party sites or content and do not make any representations or warranties about them. If you decide to access any of the third party sites linked to this Site, you do so entirely at your own risk. In the event Astellas and Seagen endorse a particular organization, Astellas and Seagen will clearly state their endorsement next to any link to that organization.
DISCLAIMER OF WARRANTIES. THIS SITE, INCLUDING ANY INFORMATION, PRODUCTS, SERVICES, OR MATERIAL MADE AVAILABLE ON OR THROUGH THIS SITE, IS PROVIDED ON AN (AS IS) AND (AS AVAILABLE) BASIS. TO THE MAXIMUM EXTENT PERMITTED BY LAW, ASTELLAS AND SEAGEN EXPRESSLY DISCLAIM ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. FURTHERMORE, ASTELLAS AND SEAGEN DO NOT WARRANT THE ACCURACY OF COMPLETENESS OF ANY INFORMATION AT THIS SITE AND MAY MAKE CHANGES TO THE INFORMATION AT THIS SITE, INCLUDING TO THE PRODUCTS, SERVICES, OR PRICES DESCRIBED AT THIS SITE, AT ANY TIME WITHOUT PRIOR NOTICE TO USERS OF THIS SITE. INFORMATION AT THIS SITE THAT IS PERIODICALLY UPDATED MAY NOT BE CURRENT AT THE MOMENT YOU VISIT THIS SITE AND MAY CONTAIN ERRORS. ASTELLAS AND SEAGEN MAKE NO WARRANTY THAT THE SITE WILL MEET YOUR REQUIREMENTS; THAT THE SITE WILL BE UNINTERRUPTED, TIMELY, SECURE, OR ERROR FREE; THAT MESSAGES OR REQUEST WILL BE DELIVERED; THAT DEFECTS WILL BE CORRECTED; OR THAT THIS SITE IS FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. ASTELLAS AND SEAGEN MAKE NO WARRANTY REGARDING ANY GOODS OR SERVICES PURCHASED OR OBTAINED THROUGH THE SITE OR ANY TRANSACTIONS ENTERED INTO THROUGH THE SITE. YOU ASSUME THE ENTIRE RISK AS TO THE RESULTS AND PERFORMANCE OF THE SITE AND ANY GOODS OR SERVICES PURCHASED THEREFROM.
LIMITATION OF LIABILITY. IN NO EVENT WILL ASTELLAS OR SEAGEN BE LIABLE FOR ANY DAMAGES WHATSOEVER, INCLUDING BUT NOT LIMITED TO DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, AND CONSEQUENTIAL DAMAGES (INCLUDING WITHOUT LIMITATION THOSE RESULTING FROM LOST PROFITS, LOST DATA OR BUSINESS INTERRUPTION) ARISING OUT OF THE USE, INABILITY TO USE, OR THE RESULT OF USE OF THIS SITE, ANY WEB SITES LINKED TO THIS SITE, THE MATERIALS OR INFORMATION CONTAINED AT ANY OR ALL SUCH SITES, OR THE MATERIALS, PRODUCTS OR SERVICES OFFERED ON THIS SITE OR SITES LINKED TO THIS SITE, WHETHER BASED ON WARRANTY, CONTRACT, TORT OR ANY OTHER LEGAL THEORY AND WHETHER OR NOT ADVISED ON THE POSSIBILITY OF SUCH DAMAGES. IN NO EVENT WILL ASTELLAS OR SEAGEN, THEIR SUPPLIERS, OR ANY OTHER PARTY INVOLVED IN CREATING, PRODUCING, OR DELIVERING THIS SITE BE LIABLE TO YOU IN ANY MANNER WHATSOEVER FOR ANY DESIGN MADE OR ACTION OR NON-ACTION TAKEN BY YOU IN RELIANCE UPON INFORMATION PROVIDED THROUGH THIS SITE. APPLICABLE LAW MAY NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL DAMAGES SO THE ABOVE LIMITATION OR EXCLUSION MAY NOT APPLY TO YOU.
THIS SITE IS INTENDED FOR U.S. AUDIENCES ONLY. Access to and use of this Site is subject to the above terms and conditions. This Site was developed and is maintained by Astellas and Seagen. Product information, copy and claims are intended only for the residents of the United States.
Back to top
Important Safety Information
IMPORTANT SAFETY INFORMATION/WHAT IS PADCEV®?
IMPORTANT SAFETY INFORMATION/
WHAT IS PADCEV®?
What is the most important information I should know about PADCEV?
PADCEV may cause serious side effects, including:
Skin reactions. Skin reactions including severe skin reactions have happened in people treated with PADCEV and may be more common when PADCEV is given with pembrolizumab. In some cases, these severe skin reactions have caused death. Most severe skin reactions occurred during the first cycle of treatment but may happen later. Your healthcare provider will monitor you, may stop your treatment with PADCEV completely or for a period of time (temporarily), may change your dose, and may prescribe medicines if you get skin reactions. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction:
• Target lesions (skin reactions that look like rings)
• Rash or itching that continues to get worse
• Blistering or peeling of the skin
• Painful sores or ulcers in mouth or nose, throat, or genital area
• Fever or flu-like symptoms
• Swollen lymph nodes
See “What are the possible side effects of PADCEV?” for more information about side effects.
Before receiving PADCEV, tell your healthcare provider about all of your medical conditions, including if you:
• Are currently experiencing numbness or tingling in your hands or feet.
• Have a history of high blood sugar or diabetes.
• Have liver problems.
• Are pregnant or plan to become pregnant. PADCEV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with PADCEV.
• Are breastfeeding or plan to breastfeed. It is not known if PADCEV passes into your breast milk. Do not breastfeed during treatment and for 3 weeks after the last dose of PADCEV.
Females who are able to become pregnant:
• Your healthcare provider should do a pregnancy test before you start treatment with PADCEV.
• You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of PADCEV.
Males with a female sexual partner who is able to become pregnant:
• If your female partner is pregnant, PADCEV can harm the unborn baby.
• You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of PADCEV.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking PADCEV with certain other medicines may cause side effects.
What are the possible side effects of PADCEV?
PADCEV may cause serious side effects, including:
Skin Reactions. See “What is the most important information I should know about PADCEV?”
High blood sugar (hyperglycemia). An increase in blood sugar is common during treatment with PADCEV. Severe high blood sugar, a serious condition called diabetic ketoacidosis (DKA), and death have happened in people with and without diabetes treated with PADCEV. Tell your healthcare provider right away if you have any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.
Lung problems. PADCEV may cause severe or life-threatening inflammation of the lungs that can lead to death. These severe problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.
Nerve problems. Nerve problems, called peripheral neuropathy, are common during treatment with PADCEV and can sometimes be severe. Nerve problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet or muscle weakness.
Eye problems. Certain eye problems are common during treatment with PADCEV. Tell your healthcare provider right away if you have dry eyes, increased tearing, blurred vision, or any vision changes. You may use artificial tear substitutes to help prevent or treat dry eyes.
Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation). If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, blister, peeling skin or discomfort at the infusion site.
Your healthcare provider may decrease your dose of PADCEV, or temporarily or completely stop your treatment with PADCEV if you have severe side effects.
If your healthcare provider prescribes PADCEV in combination with pembrolizumab for you, also read the Medication Guide that comes with pembrolizumab for important information about pembrolizumab.
The most common side effects of PADCEV when used in combination with pembrolizumab include:
• Changes in liver function and kidney function tests
• Rash. See “What is the most important information I should know about PADCEV?”
• Increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”
• Numbness or tingling in your hands or feet. See “Nerve problems”
• Increased lipase (a test done to check your pancreas)
• Decreased white blood cell, red blood cell, and platelet counts
• Tiredness
• Decreased sodium, phosphate, and protein (albumin) in the blood
• Itching
• Diarrhea
• Hair loss
• Decreased weight
• Decreased appetite
• Increased uric acid in the blood
• Increased or decreased potassium
• Dry eye. See “Eye problems”
• Nausea
• Constipation
• Change in sense of taste
• Urinary tract infection
The most common side effects of PADCEV when used alone include:
• Increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”
• Changes in liver and kidney function tests
• Decreased white blood cell, red blood cell, and platelet counts
• Rash. See “What is the most important information I should know about PADCEV?”
• Tiredness
• Numbness or tingling in your hands or feet. See “Nerve problems”
• Decreased protein (albumin), sodium, and phosphate in the blood
• Hair loss
• Decreased appetite
• Diarrhea
• Nausea
• Itching
• Increased uric acid in the blood
• Dry eye. See “Eye problems”
• Change in sense of taste
• Constipation
• Increased lipase (a blood test done to check your pancreas)
• Decreased weight
• Stomach (abdominal) pain
• Dry skin
PADCEV may cause fertility problems in females and males, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.
These are not all the possible side effects of PADCEV.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
WHAT IS PADCEV®?
PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery.
• PADCEV may be used with pembrolizumab (also known as Keytruda®), or
• PADCEV may be used alone if you:
–have received an immunotherapy medicine and chemotherapy that contains platinum, or
–are not able to receive a chemotherapy that contains the medicine cisplatin and you have received 1 or more prior therapy.
It is not known if PADCEV is safe and effective in children.
Please see full Prescribing Information/Patient Information for more information, including risk of Serious Side Effects.
Important Safety Information
IMPORTANT SAFETY INFORMATION/WHAT IS PADCEV®?
IMPORTANT SAFETY INFORMATION/
WHAT IS PADCEV®?
What is the most important information I should know about PADCEV?
PADCEV may cause serious side effects, including:
Skin reactions. Skin reactions including severe skin reactions have happened in people treated with PADCEV and may be more common when PADCEV is given with pembrolizumab. In some cases, these severe skin reactions have caused death. Most severe skin reactions occurred during the first cycle of treatment but may happen later. Your healthcare provider will monitor you, may stop your treatment with PADCEV completely or for a period of time (temporarily), may change your dose, and may prescribe medicines if you get skin reactions. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction:
• Target lesions (skin reactions that look like rings)
• Rash or itching that continues to get worse
• Blistering or peeling of the skin
• Painful sores or ulcers in mouth or nose, throat, or genital area
• Fever or flu-like symptoms
• Swollen lymph nodes
See “What are the possible side effects of PADCEV?” for more information about side effects.
Before receiving PADCEV, tell your healthcare provider about all of your medical conditions, including if you:
• Are currently experiencing numbness or tingling in your hands or feet.
• Have a history of high blood sugar or diabetes.
• Have liver problems.
• Are pregnant or plan to become pregnant. PADCEV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with PADCEV.
• Are breastfeeding or plan to breastfeed. It is not known if PADCEV passes into your breast milk. Do not breastfeed during treatment and for 3 weeks after the last dose of PADCEV.
Females who are able to become pregnant:
• Your healthcare provider should do a pregnancy test before you start treatment with PADCEV.
• You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of PADCEV.
Males with a female sexual partner who is able to become pregnant:
• If your female partner is pregnant, PADCEV can harm the unborn baby.
• You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of PADCEV.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking PADCEV with certain other medicines may cause side effects.
What are the possible side effects of PADCEV?
PADCEV may cause serious side effects, including:
Skin Reactions. See “What is the most important information I should know about PADCEV?”
High blood sugar (hyperglycemia). An increase in blood sugar is common during treatment with PADCEV. Severe high blood sugar, a serious condition called diabetic ketoacidosis (DKA), and death have happened in people with and without diabetes treated with PADCEV. Tell your healthcare provider right away if you have any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.
Lung problems. PADCEV may cause severe or life-threatening inflammation of the lungs that can lead to death. These severe problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.
Nerve problems. Nerve problems, called peripheral neuropathy, are common during treatment with PADCEV and can sometimes be severe. Nerve problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet or muscle weakness.
Eye problems. Certain eye problems are common during treatment with PADCEV. Tell your healthcare provider right away if you have dry eyes, increased tearing, blurred vision, or any vision changes. You may use artificial tear substitutes to help prevent or treat dry eyes.
Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation). If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, blister, peeling skin or discomfort at the infusion site.
Your healthcare provider may decrease your dose of PADCEV, or temporarily or completely stop your treatment with PADCEV if you have severe side effects.
If your healthcare provider prescribes PADCEV in combination with pembrolizumab for you, also read the Medication Guide that comes with pembrolizumab for important information about pembrolizumab.
The most common side effects of PADCEV when used in combination with pembrolizumab include:
• Changes in liver function and kidney function tests
• Rash. See “What is the most important information I should know about PADCEV?”
• Increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”
• Numbness or tingling in your hands or feet. See “Nerve problems”
• Increased lipase (a test done to check your pancreas)
• Decreased white blood cell, red blood cell, and platelet counts
• Tiredness
• Decreased sodium, phosphate, and protein (albumin) in the blood
• Itching
• Diarrhea
• Hair loss
• Decreased weight
• Decreased appetite
• Increased uric acid in the blood
• Increased or decreased potassium
• Dry eye. See “Eye problems”
• Nausea
• Constipation
• Change in sense of taste
• Urinary tract infection
The most common side effects of PADCEV when used alone include:
• Increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”
• Changes in liver and kidney function tests
• Decreased white blood cell, red blood cell, and platelet counts
• Rash. See “What is the most important information I should know about PADCEV?”
• Tiredness
• Numbness or tingling in your hands or feet. See “Nerve problems”
• Decreased protein (albumin), sodium, and phosphate in the blood
• Hair loss
• Decreased appetite
• Diarrhea
• Nausea
• Itching
• Increased uric acid in the blood
• Dry eye. See “Eye problems”
• Change in sense of taste
• Constipation
• Increased lipase (a blood test done to check your pancreas)
• Decreased weight
• Stomach (abdominal) pain
• Dry skin
PADCEV may cause fertility problems in females and males, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.
These are not all the possible side effects of PADCEV.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
WHAT IS PADCEV®?
PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery.
• PADCEV may be used with pembrolizumab (also known as Keytruda®), or
• PADCEV may be used alone if you:
–have received an immunotherapy medicine and chemotherapy that contains platinum, or
–are not able to receive a chemotherapy that contains the medicine cisplatin and you have received 1 or more prior therapy.
It is not known if PADCEV is safe and effective in children.
Please see full Prescribing Information/Patient Information for more information, including risk of Serious Side Effects.
Important Safety Information
IMPORTANT SAFETY INFORMATION/WHAT IS PADCEV®?
IMPORTANT SAFETY INFORMATION/
WHAT IS PADCEV®?
What is the most important information I should know about PADCEV?
PADCEV may cause serious side effects, including:
Skin reactions. Skin reactions including severe skin reactions have happened in people treated with PADCEV and may be more common when PADCEV is given with pembrolizumab. In some cases, these severe skin reactions have caused death. Most severe skin reactions occurred during the first cycle of treatment but may happen later. Your healthcare provider will monitor you, may stop your treatment with PADCEV completely or for a period of time (temporarily), may change your dose, and may prescribe medicines if you get skin reactions. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction:
• Target lesions (skin reactions that look like rings)
• Rash or itching that continues to get worse
• Blistering or peeling of the skin
• Painful sores or ulcers in mouth or nose, throat, or genital area
• Fever or flu-like symptoms
• Swollen lymph nodes
See “What are the possible side effects of PADCEV?” for more information about side effects.
Before receiving PADCEV, tell your healthcare provider about all of your medical conditions, including if you:
• Are currently experiencing numbness or tingling in your hands or feet.
• Have a history of high blood sugar or diabetes.
• Have liver problems.
• Are pregnant or plan to become pregnant. PADCEV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with PADCEV.
• Are breastfeeding or plan to breastfeed. It is not known if PADCEV passes into your breast milk. Do not breastfeed during treatment and for 3 weeks after the last dose of PADCEV.
Females who are able to become pregnant:
• Your healthcare provider should do a pregnancy test before you start treatment with PADCEV.
• You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of PADCEV.
Males with a female sexual partner who is able to become pregnant:
• If your female partner is pregnant, PADCEV can harm the unborn baby.
• You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of PADCEV.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking PADCEV with certain other medicines may cause side effects.
What are the possible side effects of PADCEV?
PADCEV may cause serious side effects, including:
Skin Reactions. See “What is the most important information I should know about PADCEV?”
High blood sugar (hyperglycemia). An increase in blood sugar is common during treatment with PADCEV. Severe high blood sugar, a serious condition called diabetic ketoacidosis (DKA), and death have happened in people with and without diabetes treated with PADCEV. Tell your healthcare provider right away if you have any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.
Lung problems. PADCEV may cause severe or life-threatening inflammation of the lungs that can lead to death. These severe problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.
Nerve problems. Nerve problems, called peripheral neuropathy, are common during treatment with PADCEV and can sometimes be severe. Nerve problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet or muscle weakness.
Eye problems. Certain eye problems are common during treatment with PADCEV. Tell your healthcare provider right away if you have dry eyes, increased tearing, blurred vision, or any vision changes. You may use artificial tear substitutes to help prevent or treat dry eyes.
Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation). If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, blister, peeling skin or discomfort at the infusion site.
Your healthcare provider may decrease your dose of PADCEV, or temporarily or completely stop your treatment with PADCEV if you have severe side effects.
If your healthcare provider prescribes PADCEV in combination with pembrolizumab for you, also read the Medication Guide that comes with pembrolizumab for important information about pembrolizumab.
The most common side effects of PADCEV when used in combination with pembrolizumab include:
• Changes in liver function and kidney function tests
• Rash. See “What is the most important information I should know about PADCEV?”
• Increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”
• Numbness or tingling in your hands or feet. See “Nerve problems”
• Increased lipase (a test done to check your pancreas)
• Decreased white blood cell, red blood cell, and platelet counts
• Tiredness
• Decreased sodium, phosphate, and protein (albumin) in the blood
• Itching
• Diarrhea
• Hair loss
• Decreased weight
• Decreased appetite
• Increased uric acid in the blood
• Increased or decreased potassium
• Dry eye. See “Eye problems”
• Nausea
• Constipation
• Change in sense of taste
• Urinary tract infection
The most common side effects of PADCEV when used alone include:
• Increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)”
• Changes in liver and kidney function tests
• Decreased white blood cell, red blood cell, and platelet counts
• Rash. See “What is the most important information I should know about PADCEV?”
• Tiredness
• Numbness or tingling in your hands or feet. See “Nerve problems”
• Decreased protein (albumin), sodium, and phosphate in the blood
• Hair loss
• Decreased appetite
• Diarrhea
• Nausea
• Itching
• Increased uric acid in the blood
• Dry eye. See “Eye problems”
• Change in sense of taste
• Constipation
• Increased lipase (a blood test done to check your pancreas)
• Decreased weight
• Stomach (abdominal) pain
• Dry skin
PADCEV may cause fertility problems in females and males, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.
These are not all the possible side effects of PADCEV.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
WHAT IS PADCEV®?
PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery.
• PADCEV may be used with pembrolizumab (also known as Keytruda®), or
• PADCEV may be used alone if you:
–have received an immunotherapy medicine and chemotherapy that contains platinum, or
–are not able to receive a chemotherapy that contains the medicine cisplatin and you have received 1 or more prior therapy.
It is not known if PADCEV is safe and effective in children.
Please see full Prescribing Information/Patient Information for more information, including risk of Serious Side Effects.
© 2024 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 01/24
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
Seagen and the Seagen logo are registered trademarks of Seagen Inc.
PADCEV Support SolutionsSM, a component of Astellas Pharma Support SolutionsSM, is a service mark jointly owned by Agensys, Inc., and Seagen Inc.
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
All other marks referenced herein are the property of their respective owners.
© 2024 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 01/24
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
Seagen and the Seagen logo are registered trademarks of Seagen Inc.
PADCEV Support SolutionsSM, a component of Astellas Pharma Support SolutionsSM, is a service mark jointly owned by Agensys, Inc., and Seagen Inc.
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
All other marks referenced herein are the property of their respective owners.
© 2024 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 01/24
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
Seagen and the Seagen logo are registered trademarks of Seagen Inc.
PADCEV Support SolutionsSM, a component of Astellas Pharma Support SolutionsSM, is a service mark jointly owned by Agensys, Inc., and Seagen Inc.
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
All other marks referenced herein are the property of their respective owners.
© 2024 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 01/24
PADCEV® and the PADCEV device are trademarks jointly owned by Agensys, Inc., and Seagen Inc.
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
Seagen and the Seagen logo are registered trademarks of Seagen Inc.
PADCEV Support SolutionsSM, a component of Astellas Pharma Support SolutionsSM, is a service mark jointly owned by Agensys, Inc., and Seagen Inc.
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
All other marks referenced herein are the property of their respective owners.
